Full Press Release Details
BridgeBio Pharma, Inc. Reports Third Quarter 2021 Financial Results And Business Update.
BBIO
BridgeBio Pharma, Inc. Reports Third Quarter 2021 Financial Results And Business Update
Key Takeaway: BridgeBio Pharma, Inc. Reports Third Quarter 2021 Financial Results And Business Update
Price reaction · baseline $51.62 (2021-11-08 close) · hit after-hours · clean, no other BBIO news in the window
day 0 close · peak
-1.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis